Newron Pharmaceuticals S.p.A. Receives FDA Notice of Clinical Hold on Phase‑III ENIGMA‑TRS 2 Study
Newron Pharmaceuticals S.p.A. (Newron) today disclosed that it has received a written notice from the U.S. Food and Drug Administration (FDA) instituting a clinical hold at all U.S. sites participating in its Phase‑III ENIGMA‑TRS 2 trial of the investigational drug evenamide. The hold is specific to the United States and does not affect ongoing enrollment in the international ENIGMA‑TRS 1 trial.
FDA’s Rationale and Safety Concerns
The FDA’s notice cites the well‑documented class effect of sodium‑channel blockers to provoke arrhythmias and, in rare instances, serious cardiovascular events or seizures. Evenamide is a selective voltage‑gated sodium‑channel blocker that functions as a glutamate modulator. Although prior studies have reported a small number of fatalities and a modest shortening of the QTc interval, Newron’s extensive pre‑clinical and clinical safety dataset—including over 10,000 electrocardiograms (ECGs) from approximately 700 patients—has not revealed a pattern of cardiac arrhythmias or other serious cardiovascular abnormalities.
The FDA’s primary concerns, therefore, focus on the theoretical risk of arrhythmogenicity associated with sodium‑channel blockade rather than on observed clinical events within Newron’s data. In response, the company is reviewing the full safety dataset and evaluating additional cardiac screening and monitoring measures that could mitigate potential risks in the U.S. population.
Impact on ENIGMA‑TRS Trial Activities
- ENIGMA‑TRS 1 (International) – Enrollment continues unabated. The trial is projected to conclude recruiting by mid‑October, with 12‑week topline results slated for release in the first quarter of 2027.
- ENIGMA‑TRS 2 (U.S. Sites) – The clinical hold suspends all U.S. site activities. Recruitment will persist in international sites, and additional non‑U.S. sites will be added according to the study protocol.
Planned Corporate Response
Newron is conducting a thorough review of the FDA’s feedback and the complete safety dataset. The company will prepare a formal written response that will address the agency’s concerns, propose enhanced cardiac monitoring protocols (e.g., baseline and periodic ECGs, telemetry for high‑risk subgroups), and outline any additional pharmacovigilance measures. The response will be submitted to the FDA once the internal review is complete.
Investor Communications
Executive management will discuss the FDA hold, the status of the ENIGMA‑TRS program, and the company’s mitigation strategy during an upcoming investor conference call. The call will also cover projected timelines for the resumption of U.S. site operations and potential impacts on commercial projections.
Key Takeaways for Healthcare Professionals and Patients
| Topic | Evidence‑Based Insight |
|---|---|
| Safety Profile | No consistent evidence of cardiac arrhythmias in >10,000 ECGs; risk remains theoretical. |
| Efficacy Outcomes | Phase‑III data pending; ENIGMA‑TRS 1 expected to provide 12‑week efficacy signals in Q1 2027. |
| Regulatory Pathway | Clinical hold is a temporary FDA measure; company is preparing a detailed safety mitigation plan. |
| Patient Care Implications | Patients enrolled outside the U.S. will continue under the current protocol; U.S. patients awaiting future enrollment may be delayed. |
| Healthcare System Impact | Potential delay in drug availability in the U.S. market; ongoing monitoring may affect resource allocation for cardiac surveillance. |
This update underscores the importance of rigorous safety assessment for novel ion‑channel modulators and highlights the FDA’s role in safeguarding patient health while advancing therapeutic innovation.
